☰

Benjamin Doranz - Publications

Affiliations: 
Integral Molecular 
Tree Info Similar researchers PubMed Report error

34 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Jensen JL, Sankhala RS, Dussupt V, Bai H, Hajduczki A, Lal KG, Chang WC, Martinez EJ, Peterson CE, Golub ES, Rees PA, Mendez-Rivera L, Zemil M, Kavusak E, Mayer SV, ... ... Doranz BJ, et al. Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity. Journal of Virology. e0159622. PMID 37395646 DOI: 10.1128/jvi.01596-22  0.313
2023 Chen WH, Hajduczki A, Martinez EJ, Bai H, Matz H, Hill TM, Lewitus E, Chang WC, Dawit L, Peterson CE, Rees PA, Ajayi AB, Golub ES, Swafford I, Dussupt V, ... ... Doranz BJ, et al. Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity. Nature Communications. 14: 580. PMID 36737435 DOI: 10.1038/s41467-023-36106-x  0.329
2022 Tsuji I, Vang F, Dominguez D, Karwal L, Sanjali A, Livengood JA, Davidson E, Fouch ME, Doranz BJ, Das SC, Dean HJ. Somatic Hypermutation and Framework Mutations of Variable Region Contribute to Anti-Zika Virus-Specific Monoclonal Antibody Binding and Function. Journal of Virology. e0007122. PMID 35575481 DOI: 10.1128/jvi.00071-22  0.302
2022 Suryadevara N, Shiakolas AR, VanBlargan LA, Binshtein E, Chen RE, Case JB, Kramer KJ, Armstrong EC, Myers L, Trivette A, Gainza C, Nargi RS, Selverian CN, Davidson E, Doranz BJ, et al. An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer. The Journal of Clinical Investigation. PMID 35472136 DOI: 10.1172/JCI159062  0.328
2022 Yuan TZ, Garg P, Wang L, Willis JR, Kwan E, Hernandez AGL, Tuscano E, Sever EN, Keane E, Soto C, Mucker EM, Fouch ME, Davidson E, Doranz BJ, Kailasan S, et al. Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries. Mabs. 14: 2002236. PMID 34967699 DOI: 10.1080/19420862.2021.2002236  0.316
2021 Dussupt V, Sankhala RS, Mendez-Rivera L, Townsley SM, Schmidt F, Wieczorek L, Lal KG, Donofrio GC, Tran U, Jackson ND, Zaky WI, Zemil M, Tritsch SR, Chen WH, Martinez EJ, ... ... Doranz BJ, et al. Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations. Nature Immunology. PMID 34716452 DOI: 10.1038/s41590-021-01068-z  0.316
2021 Williamson LE, Reeder KM, Bailey K, Tran MH, Roy V, Fouch ME, Kose N, Trivette A, Nargi RS, Winkler ES, Kim AS, Gainza C, Rodriguez J, Armstrong E, Sutton RE, ... ... Doranz BJ, et al. Therapeutic alphavirus cross-reactive E1 human antibodies inhibit viral egress. Cell. 184: 4430-4446.e22. PMID 34416147 DOI: 10.1016/j.cell.2021.07.033  0.307
2021 Kotaki T, Kurosu T, Grinyo-Escuer A, Davidson E, Churrotin S, Okabayashi T, Puiprom O, Mulyatno KC, Sucipto TH, Doranz BJ, Ono KI, Soegijanto S, Kameoka M. An affinity-matured human monoclonal antibody targeting fusion loop epitope of dengue virus with in vivo therapeutic potency. Scientific Reports. 11: 12987. PMID 34155267 DOI: 10.1038/s41598-021-92403-9  0.318
2021 Murin CD, Gilchuk P, Ilinykh PA, Huang K, Kuzmina N, Shen X, Bruhn JF, Bryan AL, Davidson E, Doranz BJ, Williamson LE, Copps J, Alkutkar T, Flyak AI, Bukreyev A, et al. Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies. Cell Reports. 35: 108984. PMID 33852862 DOI: 10.1016/j.celrep.2021.108984  0.305
2021 Suryadevara N, Shrihari S, Gilchuk P, VanBlargan LA, Binshtein E, Zost SJ, Nargi RS, Sutton RE, Winkler ES, Chen EC, Fouch ME, Davidson E, Doranz BJ, Chen RE, Shi PY, et al. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell. PMID 33773105 DOI: 10.1016/j.cell.2021.03.029  0.329
2021 Suryadevara N, Shrihari S, Gilchuk P, VanBlargan LA, Binshtein E, Zost SJ, Nargi RS, Sutton RE, Winkler ES, Chen EC, Fouch ME, Davidson E, Doranz BJ, Carnahan RH, Thackray LB, et al. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Biorxiv : the Preprint Server For Biology. PMID 33501445 DOI: 10.1101/2021.01.19.427324  0.329
2021 Ku Z, Xie X, Davidson E, Ye X, Su H, Menachery VD, Li Y, Yuan Z, Zhang X, Muruato AE, I Escuer AG, Tyrell B, Doolan K, Doranz BJ, Wrapp D, et al. Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. Nature Communications. 12: 469. PMID 33473140 DOI: 10.1038/s41467-020-20789-7  0.322
2020 Gilchuk P, Murin CD, Milligan JC, Cross RW, Mire CE, Ilinykh PA, Huang K, Kuzmina N, Altman PX, Hui S, Gunn BM, Bryan AL, Davidson E, Doranz BJ, Turner HL, et al. Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization. Immunity. PMID 32023489 DOI: 10.1016/J.Immuni.2020.01.001  0.302
2020 Stafford LJ, Willis S, Rucker J, Doranz B, Chambers R. Abstract 527: Isolation of large and diverse monoclonal antibody panels against the multipass membrane protein targets Kv1.3, P2X7, and Claudin 18.2 Cancer Research. 80: 527-527. DOI: 10.1158/1538-7445.Am2020-527  0.37
2020 Prabhu V, Cuoco C, Jung J, Morrow S, Kawakibi AR, Willette B, Day M, Anantharaman L, Charter N, Rucker J, Doranz B, Basken J, Stogniew M, Gilbert M, Free R, et al. DDRE-33. MOLECULAR DIFFERENTIATION OF IMIPRIDONES ONC201 AND ONC206 Neuro-Oncology. 22: ii68-ii68. DOI: 10.1093/neuonc/noaa215.278  0.333
2019 Williamson L, Flyak AI, Kose N, Bombardi R, Branchizio A, Reddy S, Davidson E, Doranz B, Fusco ML, Saphire EO, Halfmann PJ, Kawaoka Y, Piper AE, Glass PJ, Crowe JE. Early human B cell response to Ebola virus in four U.S. survivors of infection. Journal of Virology. PMID 30728263 DOI: 10.1128/Jvi.01439-18  0.359
2019 Benjamin Free R, Cuoco C, Prabhu V, Willette B, Day M, Anantharaman L, Sulli C, Davidson E, Deacon S, Rucker J, Charter N, Doranz B, Oster W, Stogniew M, Robert Lane J, et al. EXTH-33. RECEPTOR PHARMACOLOGY OF ONC201: THE FIRST BITOPIC DRD2 ANTAGONIST FOR CLINICAL NEURO-ONCOLOGY Neuro-Oncology. 21: vi89-vi89. DOI: 10.1093/Neuonc/Noz175.365  0.438
2019 Prabhu V, Cuoco C, Jung J, Rahman Kawakibi A, Willette B, Day M, Anantharaman L, Charter N, Rucker J, Doranz B, Oster W, Stogniew M, Gilbert M, Benjamin Free R, Sibley D, et al. DDIS-20. IMIPRIDONE STRUCTURE ACTIVITY RELATIONSHIP UNCOVERS ONC206 AS THE NEXT BITOPIC DRD2 ANTAGONIST FOR ONCOLOGY WITH DIFFERENTIATED RECEPTOR PHARMACOLOGY Neuro-Oncology. 21: vi67-vi67. DOI: 10.1093/Neuonc/Noz175.271  0.418
2018 Gilchuk P, Kuzmina N, Ilinykh PA, Huang K, Gunn BM, Bryan A, Davidson E, Doranz BJ, Turner HL, Fusco ML, Bramble MS, Hoff NA, Binshtein E, Kose N, Flyak AI, et al. Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. Immunity. PMID 30029854 DOI: 10.1016/J.Immuni.2018.06.018  0.301
2018 Stafford LJ, Screnci B, Sulli C, Rosenberg E, Molino N, Tucker D, Sullivan J, Barnes T, Pfaff J, Hazarika T, Charpentier T, Gilman S, Rimkunas R, Wilf R, Willis S, ... Doranz B, et al. Abstract 5759: Discovery of a novel claudin 6 (CLDN6) specific monoclonal antibody Cancer Research. 78: 5759-5759. DOI: 10.1158/1538-7445.Am2018-5759  0.388
2018 Prabhu VV, Madhukar N, Tarapore R, Garnett M, McDermott U, Benes C, Charter N, Deacon S, VanEngelenburg A, Rucker J, Doranz B, Elemento O, Oster W, Stogniew M, Allen J. Abstract 4874: Receptor pharmacology and anti-cancer activity of selective DRD2/3 antagonist imipridone ONC206 Cancer Research. 78: 4874-4874. DOI: 10.1158/1538-7445.Am2018-4874  0.44
2018 Prabhu VV, Madhukar N, Kline CLB, Tarapore R, El-Deiry WS, Rucker J, Doranz B, Doherty F, VanEngelenburg A, Durrant J, Benes C, Deacon S, Charter N, Free RB, Oster W, et al. Abstract 3857: Selective targeting of dopamine receptor dysregulation in high grade gliomas with imipridone ONC201 Cancer Research. 78: 3857-3857. DOI: 10.1158/1538-7445.Am2018-3857  0.445
2018 Madhukar NS, Prabhu VV, Anantharaman L, Sulli C, Davidson E, Deacon S, Rucker J, Charter N, Doranz B, Oster W, Elemento O, Free RB, Sibley D, Allen JE. Abstract B130: Differentiated pharmacology of the imipridone ONC201: the first selective DRD2/3 antagonist in clinical oncology Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B130  0.45
2018 Prabhu VV, Madhukar N, Tarapore R, Garnett M, McDermott U, Benes C, Anantharaman L, Charter N, Deacon S, VanEngelenburg A, Rucker J, Doranz B, Rusert J, Wechsler-Reya R, Elemento O, et al. EXTH-17. SELECTIVE, NON-COMPETITIVE DRD2/3 ANTAGONISM BY IMIPRIDONE ONC206 IS EFFECTIVE IN TUMORS WITH DOPAMINE RECEPTOR DYSREGULATION Neuro-Oncology. 20: vi88-vi88. DOI: 10.1093/Neuonc/Noy148.366  0.35
2018 Vijay Prabhu V, Madhukar N, Anantharaman L, Sulli C, Davidson E, Deacon S, Tarapore R, Rucker J, Charter N, Doranz B, Oster W, Stogniew M, Elemento O, Free RB, Sibley D, et al. DDIS-12. ONC201: THE FIRST SELECTIVE, NON-COMPETITIVE DRD2/3 ANTAGONIST FOR CLINICAL NEURO-ONCOLOGY Neuro-Oncology. 20: vi71-vi71. DOI: 10.1093/Neuonc/Noy148.291  0.306
2017 Madhukar N, Prabhu VV, Anantharaman L, Sulli C, Davidson E, Deacon S, Tarapore R, Rucker J, Charter N, Doranz B, Oster W, Elemento O, Free RB, Sibley D, Allen JE. EXTH-43. DIFFERENTIATED PHARMACOLOGY OF THE IMIPRIDONE ONC201, THE FIRST SELECTIVE DRD2/3 ANTAGONIST IN CLINICAL NEURO-ONCOLOGY Neuro-Oncology. 19: vi81-vi82. DOI: 10.1093/Neuonc/Nox168.335  0.456
2016 Howell KA, Qiu X, Brannan JM, Bryan C, Davidson E, Holtsberg FW, Wec AZ, Shulenin S, Biggins JE, Douglas R, Enterlein SG, Turner HL, Pallesen J, Murin CD, He S, ... ... Doranz BJ, et al. Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site. Cell Reports. PMID 27160900 DOI: 10.1016/J.Celrep.2016.04.026  0.312
2016 Flyak AI, Shen X, Murin CD, Turner HL, David JA, Fusco ML, Lampley R, Kose N, Ilinykh PA, Kuzmina N, Branchizio A, King H, Brown L, Bryan C, Davidson E, ... Doranz BJ, et al. Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection. Cell. PMID 26806128 DOI: 10.1016/J.Cell.2015.12.022  0.31
2015 Jin J, Liss NM, Chen DH, Liao M, Fox JM, Shimak RM, Fong RH, Chafets D, Bakkour S, Keating S, Fomin ME, Muench MO, Sherman MB, Doranz BJ, Diamond MS, et al. Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis. Cell Reports. PMID 26686638 DOI: 10.1016/J.Celrep.2015.11.043  0.301
2015 Smith SA, Nivarthi UK, de Alwis R, Kose N, Sapparapu G, Bombardi R, Kahle KM, Pfaff JM, Lieberman S, Doranz BJ, de Silva AM, Crowe JE. Dengue virus prM-specific human monoclonal antibodies with virus replication enhancing properties recognize a single immunodominant antigenic site. Journal of Virology. PMID 26512092 DOI: 10.1128/Jvi.01805-15  0.334
2013 Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, Pfaff JM, Xiang X, Doranz BJ, de Silva AM, Austin SK, Sukupolvi-Petty S, Diamond MS, Crowe JE. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. Mbio. 4: e00873-13. PMID 24255124 DOI: 10.1128/Mbio.00873-13  0.305
2013 Costin JM, Zaitseva E, Kahle KM, Nicholson CO, Rowe DK, Graham AS, Bazzone LE, Hogancamp G, Figueroa Sierra M, Fong RH, Yang ST, Lin L, Robinson JE, Doranz BJ, Chernomordik LV, et al. Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop. Journal of Virology. 87: 52-66. PMID 23077306 DOI: 10.1128/JVI.02273-12  0.349
1999 Lee B, Sharron M, Blanpain C, Doranz BJ, Vakili J, Setoh P, Berg E, Liu G, Guy HR, Durell SR, Parmentier M, Chang CN, Price K, Tsang M, Doms RW. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. The Journal of Biological Chemistry. 274: 9617-26. PMID 10092648 DOI: 10.1074/Jbc.274.14.9617  0.315
1994 Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proceedings of the National Academy of Sciences of the United States of America. 91: 6196-200. PMID 8016137 DOI: 10.1073/Pnas.91.13.6196  0.308
Show low-probability matches.